ByInvesting.com • Sep 09, 2019 Novo Nordisk to cut insulin prices in the U.S. COPENHAGEN (Reuters) - Novo Nordisk (CSE:NOVOb) will offer cheaper insulin to U.S. diabetics, the Danish drugmaker ...
Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...
And speaking of dividends, Novo Nordisk pays one, and it has increased its annual dividend per share by almost 284% in the ...
Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...
Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and ...
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on October 18 to review and discuss Novo Nordisk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback